GSK
808 hedge funds and large institutions have $9.68B invested in GSK in 2023 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 352 increasing their positions, 219 reducing their positions, and 69 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 219
61% more call options, than puts
Call options by funds: $269M | Put options by funds: $167M
19% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 69
0.09% less ownership
Funds ownership: 6.75% → 6.66% (-0.09%)
0% less capital invested
Capital invested by funds: $9.71B → $9.68B (-$30.4M)
1% less funds holding
Funds holding: 813 → 808 (-5)
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$214M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$167M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$55.1M |
| 4 |
Holocene Advisors
New York
|
+$41.4M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$33.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$223M |
| 2 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$139M |
| 3 |
Millennium Management
New York
|
-$119M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$112M |
| 5 |
Renaissance Technologies
New York
|
-$73.7M |
GSK Hedge Fund Activity: Q1 2023 in Review
808 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2023, worth a combined $9.68B — down 0.31% from $9.71B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new GSK positions and 69 closed out — a net gain of 13 holders — while 352 added to existing stakes and 219 trimmed.
The largest buyer was Primecap Management, adding an estimated $214M. The largest seller was Point72 Asset Management, cutting an estimated $223M.
- 808 institutional investors held GSK (GSK) as of Q1 2023, down from 813 in Q4 2022.
- Funds reported $9.68B of GSK stock for Q1 2023, down 0.31% quarter-over-quarter.
- 82 funds opened new GSK positions in Q1 2023 and 69 closed out, a net change of +13 holders.
- The largest GSK buyer in Q1 2023 was Primecap Management, an estimated $214M added.
- The largest GSK seller in Q1 2023 was Point72 Asset Management, an estimated $223M sold.
Based on aggregated 13F filings for Q1 2023.